Tuesday, 23 April 2024


Australian startup Cyteph secures $1.5 M for brain cancer immunotherapy trial

30 May 2023 | News

To address pressing, unmet needs in the treatment of cancer

Image credit: shutterstock

Image credit: shutterstock

Cyteph, a spin-out biotechnology company from QIMR Berghofer Medical Research Institute in Australia, has been awarded a $1.5 million grant via the CUREator incubator.

This grant signals an official launch milestone for the startup, supporting its imminent plan to conduct a phase 1 clinical trial for its lead candidate CYT-101 in recurrent glioblastoma multiforme (GBM) patients.

Under the guidance of QIMR Berghofer’s Professor Rajiv Khanna, the goal is to develop allogeneic or ‘off-the-shelf’ T cell therapies and a dual-targeting CAR T platform to rapidly advance the treatment of solid tumours.

CYT-101 is an allogeneic cytomegalovirus (CMV)-specific T cell therapy developed by Professor Khanna’s team. The novel immunotherapy uses the immune system and the power of virus-specific T cells to recognise and attack cancer cells. CMV-specific T cells are particularly effective at targeting and destroying virus-infected and malignant cells because they are primed in the body as killer T cells which rapidly migrate and penetrate deep into diseased tissues.

The programme has been de-risked through two previous clinical trials using autologous CMV- specific T cell therapy in GBM patients, where it was found to be safe with preliminary efficacy signals.

In addition to CYT-101, Cyteph plans to utilise the unique properties of allogenic CMV-specific T cells as a dual targeting, CAR T delivery platform ‘Cyt-ATTAC’ (Cytomegalovirus – Allogeneic Tumor TArgeting Car t) to treat solid tumours. Capital raise efforts are underway to support this promising pipeline of medical research.

 

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account